Clinical trial · Observational
Molecular Profiling in Prostate Cancer
Prognostic and Predictive Value of Tumor Molecular Alterations in Patients With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes, including also a few additional clinically relevant genes, in patients with metastatic, locally advanced or high-grade prostate cancer. In addition, we will investigate the prognostic role of these mutations as well as their association with various clinicopathological parameters. This will be the first study investigating the prevalence of germline and somatic pathogenic mutations in Greek patients with prostate cancer.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Germline BRCA1 Gene Mutation | — | UNRESOLVED | — |
| Germline BRCA2 Gene Mutation | — | UNRESOLVED | — |
| Mutation | — | UNRESOLVED | — |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumor molecular profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevalence of germline and somatic mutations in cancer predisposing genes
- timeFrame
- 1 year
- description
- Number of patients with either germline or somatic mutations
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- Time from diagnosis to the date of death, through the completion of the study
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * metastatic prostate cancer * recurrent prostate cancer * locally advanced prostate cancer * "intermediate or high risk" (Gleason \>7), operable prostate cancer * available FFPE tumor tissue Exclusion Criteria: * absence of tumor tissue available for analysis
References
Publications (0)
Data not yet available